High-dose injected amycretin beat placebo on weight in a meta-analysis

How does amycretin work?

Amycretin activates the GLP-1 receptor and the amylin receptor from a single molecule, so it does not require co-administration of two separate drugs ^[2]⁠^[3]. GLP-1 receptor agonism is mechanistically well characterized: it slows gastric emptying and reduces appetite through central and peripheral signaling. Amylin receptor agonism is a newer, less mature pharmacological target, and the literature still describes the class as "emerging" ^[1].

Amylin signaling contributes to satiety through central pathways distinct from GLP-1's, which is the biological rationale for combining the two. The combined receptor pharmacology of a single dual-agonist molecule, as opposed to two separately dosed drugs, has been characterized only in early-phase human trials ^[2]⁠^[3]. The mechanistic logic is sound, but the human data behind it are much shallower than the data behind GLP-1 monotherapy.

What did the amycretin trials measure?

The amycretin trials measured safety first; weight change was a secondary or exploratory outcome in both. The first-in-human oral trial was a single- and multiple-ascending-dose Phase 1 study at one clinical research site, and its stated aims were safety, tolerability, pharmacokinetics, and pharmacodynamics ^[3].

The subcutaneous study was a Phase 1b/2a trial, also at a single US site. It escalated weekly doses from 0.3 mg up to a 60 mg ceiling across five parallel study parts, with treatment durations up to 36 weeks, and its primary endpoint was the number of treatment-emergent adverse events, not weight loss ^[2].

Weight change in both trials was collected inside small, single-center, dose-finding studies, not as the outcome the trials were powered to detect. A headline percentage pulled from a safety-focused Phase 1 study carries a much lower evidence grade than the same percentage would carry from an adequately powered, placebo-controlled efficacy trial.

How much weight loss does amycretin produce?

High-dose subcutaneous amycretin showed a mean 23.95 percentage-point greater weight reduction than placebo in a 2026 network meta-analysis of six randomized trials of amylin-based agents ^[1]. That figure comes from the pooled analysis, not from a single trial report. The analysis ranks high-dose subcutaneous amycretin above high-dose eloralintide, high-dose CagriSema, semaglutide 2.4 mg, and liraglutide 3.0 mg on percent weight change ^[1].

The network meta-analysis is the most rigorous cross-trial comparison available. It is still a comparison across trials that differ in duration, dosing schedule, and population, a limitation inherent to network meta-analysis regardless of how carefully it is modeled.

A figure near 13% weight loss at 12 weeks for oral amycretin is widely repeated in coverage. The peer-reviewed oral Phase 1 report centers on safety and pharmacokinetics ^[3], so any weight figure from that trial is an exploratory result from a small study, not an efficacy finding.

Is amycretin better than semaglutide?

No trial has compared amycretin with semaglutide head to head, so the claim that amycretin beats semaglutide is premature ^[1]. A fair comparison requires trials of similar size, duration, and design, ideally head to head.

What exists for amycretin instead is small, short, single-site, safety-oriented early-phase data ^[2]⁠^[3], pooled by statistical modeling against other agents' trials of different lengths and populations ^[1]. The semaglutide figure in the network meta-analysis comes from separate trials, not from a study that randomized patients to either drug ^[1]. Semaglutide's evidence from three randomized trials covers the trial base on the other side of the comparison.

Are oral and subcutaneous amycretin the same?

Oral and subcutaneous amycretin are separate datasets: the two programs used different dose ranges, different titration schedules, and different maximum treatment durations ^[2]⁠^[3]. Oral peptide bioavailability is inherently lower and more variable than subcutaneous delivery ^[2]⁠^[3].

Blending their results into one "amycretin number" obscures that these are pharmacologically distinct exposures. No claim that treats the two formulations as interchangeable is supported by the cited trials. The oral semaglutide dosing explainer covers oral peptide bioavailability in a related GLP-1 drug.

What side effects does amycretin cause?

Amycretin causes GI adverse events, including nausea, vomiting, and constipation, that increase with dose ^[1]. GI adverse events are more common with oral amycretin and with amylin/GLP-1 combination approaches generally ^[1].

The network meta-analysis flags GI adverse events as more frequent with oral amycretin specifically, alongside high-dose CagriSema, than with the other agents in the comparison ^[1]. Tolerability, not just efficacy, differs by route.

Does amycretin preserve lean mass?

No amycretin trial cited below reports body composition, so lean-mass preservation is not shown for amycretin ^[2]⁠^[3]. Amylin co-agonism sparing lean tissue during weight loss is a mechanistically plausible hypothesis. The trials measured treatment-emergent adverse events, pharmacokinetics, and body weight; body composition endpoints such as DXA-measured fat versus lean mass are not reported outcomes ^[2]⁠^[3].

Repeating the lean-mass claim as confirmed for amycretin goes beyond what these trials measured. What preserves muscle during GLP-1 weight loss covers the broader lean-mass question.

Does amycretin have Phase 3 data?

Amycretin has no published Phase 3 data yet; completed amycretin work is Phase 1, 1b, and 2a ^[2]⁠^[3]. The related two-molecule amylin/GLP-1 combination, cagrilintide-semaglutide (CagriSema), shows the evidence tier amycretin still needs.

Cagrilintide-semaglutide reached a 68-week, 1,206-patient, double-blind, placebo-controlled Phase 3 trial in type 2 diabetes, with a 13.7% mean weight change versus 3.4% with placebo ^[4]. A separate 30-country Phase 3 program, REIMAGINE 2, compared the combination against its individual components ^[5]. A legitimate amycretin-versus-semaglutide claim would need evidence at that tier, and amycretin has not reached it. The cagrilintide trial review covers the amylin component of that combination.

What is still unknown about amycretin?

The cited amycretin trials leave five questions unaddressed ^[2]⁠^[3]:

• Durability. No cited trial follows amycretin beyond 36 weeks.
• GI discontinuation. Discontinuation rates from GI intolerance over longer exposure are unknown.
• Cardiovascular and metabolic outcomes. No cited trial reports them.
• Phase 3 dose. The cited trials do not establish which dose will advance to Phase 3.
• Body composition. Effects on fat versus lean mass are unreported.

Until adequately powered, longer, placebo-controlled trials report, amycretin's weight-loss evidence is an early clinical signal, not established efficacy.